Figure 4From: A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study FEV 1 AUC 0–4h treatment differences for glycopyrronium versus tiotropium on Day 1 and at Week 12 (PPS). Data are LSM ± standard error; *p < 0.001; AUC = area under the curve; FEV1 = forced expiratory volume in 1 second; PPS = per-protocol set.Back to article page